TABLE 1.
Basic demographics of the study population
| Characteristics | Results n (%) |
|---|---|
| Total no. study subjects | 2092 |
| Mean age ± SD | 47.50 ± 13.17 |
| Gender | |
| Male | 436 (20.84%) |
| Female | 1656 (79.16%) |
| Education | |
| None | 222 (10.61%) |
| Primary | 689 (32.93%) |
| Secondary | 528 (25.24%) |
| Graduate | 653 (31.21%) |
| Autoimmune rheumatic disease | |
| Rheumatoid arthritis | 1480 (70.74) |
| Systemic lupus erythematosus | 238 (11.37%) |
| Axial and peripheral spondyloarthritis | 99 (4.7%) |
| Psoriatic arthritis | 77 (3.7%) |
| Mixed connective tissue disease | 45 (2.1%) |
| Sjögren’s syndrome | 32 (1.5%) |
| Gout | 30 (1.4%) |
| Systemic sclerosis | 26 (1.24%) |
| Undifferentiated connective tissue disease | 26 (1.24%) |
| Vasculitis | 18 (0.8%) |
| Juvenile idiopathic arthritis | 8 (0.38%) |
| Sarcoidosis | 7 (0.33%) |
| Anti‐phospholipid antibody syndrome | 6 (0.28%) |
| Median disease duration (range) y | 3 (0‐33) |
| Current drugs | |
| Methotrexate | 1085 (51.84%) |
| Steroids | 995 (47.56%) |
| Hydroxychloroquine | 584 (27.91%) |
| Sulfasalazine | 434 (20.74%) |
| Leflunomide | 205 (9.79%) |
| Mycophenolate mofetil | 115 (5.4%) |
| Biologics | 85 (4.06%) |
| Iguratimod | 65 (3.1%) |
| Azathioprine | 64 (3%) |
| Janus‐activated kinase inhibitors | 14 (0.66%) |
| Allopurinol | 2 (0.09%) |
| Cyclosporine | 1 (0.04%) |
| Comorbidities | |
| Diabetes mellitus | 357 (17.06%) |
| Thyroid disorders | 318 (15.20%) |
| Systemic hypertension | 290 (13.86%) |
| Coronary artery disease | 85 (4.06%) |